ESTALIS

This brand name is authorized in Australia, Austria, Brazil, Canada, Finland, New Zealand, Poland, South Africa.

Active ingredients

The drug ESTALIS contains a combination of these active pharmaceutical ingredients (APIs):

1	Estradiol UNII CXY7B3Q98Z - ESTRADIOL HEMIHYDRATE
	Estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms. Oestrogens prevent bone loss following menopause or ovariectomy.
	Read more about Estradiol
2	Norethisterone UNII 9S44LIC7OJ - NORETHINDRONE ACETATE
	Norethisterone has progestational actions similar to those of progesterone, but is a more potent inhibitor of ovulation and has weak oestrogenic and androgenic properties. It is used to treat a number of disorders of the menstrual cycle.
	Read more about Norethisterone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03FA01	Norethisterone and estrogen	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03F Progestogens and estrogens in combination → G03FA Progestogens and estrogens, fixed combinations
Discover more medicines within G03FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8427M, 8428N
BR	Câmara de Regulação do Mercado de Medicamentos	526505401172417
CA	Health Products and Food Branch	02241835, 02241837
FI	Lääkealan turvallisuus- ja kehittämiskeskus	575990
NZ	Medicines and Medical Devices Safety Authority	10909, 10911
PL	Rejestru Produktów Leczniczych	100096652, 100096669
ZA	Health Products Regulatory Authority	37/21.8.2/0456, 37/21.8.2/0457